INTERVENTION 1:	Intervention	0
All MCS110+Carboplatin+Gemcitabine	Intervention	1
experimental. all MCS110 treated patients, with 10mg/kg intravenous infusion, on day 1 and days 1 & 8	Intervention	2
day	UO:0000033	81-84
day	UO:0000033	91-94
INTERVENTION 2:	Intervention	3
Carboplatin+Gemcitabine	Intervention	4
comparator. Gemcitabine: Intravenous infusion 1000 mg/m2 Days 1 & 8 Carboplatin: Intravenous infusion AUC 2 Days 1 & 8	Intervention	5
gemcitabine	CHEBI:175901	12-23
carboplatin	CHEBI:31355	68-79
auc	BAO:0002120	102-105
Inclusion Criteria:	Eligibility	0
Adult women ( 18 years of age) with advanced TNBC.	Eligibility	1
adult	EFO:0001272	0-5
age	PATO:0000011	26-29
Histological or cytological evidence of estrogen-receptor negative (ER-), progesterone receptor negative (PgR-) and human epidermal growth factor-2 receptor negative (HER2-) Breast Cancer by local laboratory testing, based on last available tumor tissue.	Eligibility	2
progesterone	CHEBI:17026	74-86
receptor	BAO:0000281	49-57
receptor	BAO:0000281	87-95
receptor	BAO:0000281	148-156
growth	GO:0040007	132-138
breast cancer	DOID:1612	174-187
tissue	UBERON:0000479	247-253
ER/PgR negativity to follow local guidelines	Eligibility	3
If IHC HER2 2+, a negative FISH test is required	Eligibility	4
A pre-treatment tumor biopsy demonstrating high TAM content as assessed per the central laboratory	Eligibility	5
central	HP:0030645	80-87
Patients must have:	Eligibility	6
At least one measurable lesion per RECIST 1.1. (Note: Measurable lesions include lytic or mixed (lytic + blastic) bone lesions, with an identifiable soft tissue component that meets the measurability criteria)	Eligibility	7
mixed	BAO:0002107	90-95
tissue	UBERON:0000479	154-160
Exclusion Criteria:	Eligibility	8
Prior chemotherapy for advanced BC. Previous adjuvant/neoadjuvant chemotherapy is allowed (carboplatin, cisplatin or gemcitabine only if > 12 months has passed since last administration).	Eligibility	9
carboplatin	CHEBI:31355	91-102
cisplatin	CHEBI:27899	104-113
gemcitabine	CHEBI:175901	117-128
Therapy for underlying malignancy within 2 weeks prior to start of study treatment:	Eligibility	10
Chemotherapy, biologic therapy (antibodies and biologically targeted small molecules)	Eligibility	11
Radiotherapy	Eligibility	12
radiotherapy	OAE:0000235	0-12
Major surgery	Eligibility	13
surgery	OAE:0000067	6-13
Patients receiving concomitant immunosuppressive agents or chronic corticosteroids (  10 mg of prednisone or equivalent) at the time of first study dose.	Eligibility	14
chronic	HP:0011010	59-66
prednisone	CHEBI:8382	95-105
time	PATO:0000165	128-132
Clinically significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of screening.	Eligibility	15
disease	DOID:4,OGMS:0000031	38-45
congestive heart failure	HP:0001635,DOID:6000	95-119
myocardial infarction	HP:0001658,DOID:5844	124-145
Known history of human immunodeficiency virus or active infection with hepatitis virus or any uncontrolled active systemic infection.	Eligibility	16
history	BFO:0000182	6-13
immunodeficiency	HP:0002721	23-39
virus	BAO:0000232	40-45
virus	BAO:0000232	81-86
active	PATO:0002354	49-55
active	PATO:0002354	107-113
hepatitis	HP:0012115,DOID:2237	71-80
Patients with the following laboratory values during screening and on Day 1 predose:	Eligibility	17
day	UO:0000033	70-73
Absolute Neutrophil Count (ANC) < 1.5x109/L	Eligibility	18
Hemoglobin < 9 g/dL	Eligibility	19
hemoglobin	CHEBI:35143	0-10
Platelets < 100x109/L	Eligibility	20
Serum creatinine > 1.5 x ULN	Eligibility	21
creatinine	CHEBI:16737	6-16
x	LABO:0000148	23-24
Serum total bilirubin > 1.5 x ULN	Eligibility	22
x	LABO:0000148	28-29
AST/SGOT and ALT/SGPT > 3.0 x ULN	Eligibility	23
x	LABO:0000148	28-29
Outcome Measurement:	Results	0
Progression Free Survival (PFS) as Per RECIST v1.1 (by Local Investigator Assessment)	Results	1
PFS Results presented for all MCS110 treated patients (with and without day 8 dose), in line with phase 2 study design.	Results	2
day	UO:0000033	72-75
Time frame: 4 years	Results	3
time	PATO:0000165	0-4
Results 1:	Results	4
Arm/Group Title: All MCS110+Carboplatin+Gemcitabine	Results	5
Arm/Group Description: experimental. all MCS110 treated patients, with 10mg/kg intravenous infusion, on day 1 and days 1 & 8	Results	6
day	UO:0000033	104-107
day	UO:0000033	114-117
Overall Number of Participants Analyzed: 34	Results	7
Median (90% Confidence Interval)	Results	8
median	BAO:0002174	0-6
Unit of Measure: months  5.6        (4.5 to 8.7)	Results	9
Results 2:	Results	10
Arm/Group Title: Carboplatin+Gemcitabine	Results	11
Arm/Group Description: comparator. Gemcitabine: Intravenous infusion 1000 mg/m2 Days 1 & 8 Carboplatin: Intravenous infusion AUC 2 Days 1 & 8	Results	12
gemcitabine	CHEBI:175901	35-46
carboplatin	CHEBI:31355	91-102
auc	BAO:0002120	125-128
Overall Number of Participants Analyzed: 16	Results	13
Median (90% Confidence Interval)	Results	14
median	BAO:0002174	0-6
Unit of Measure: months  5.5        (3.5 to 7.5)	Results	15
Adverse Events 1:	Adverse Events	0
Total: 10/19 (52.63%)	Adverse Events	1
Anaemia 0/19 (0.00%)	Adverse Events	2
Atypical haemolytic uraemic syndrome 1/19 (5.26%)	Adverse Events	3
syndrome	DOID:225	28-36
Thrombocytopenia 0/19 (0.00%)	Adverse Events	4
thrombocytopenia	HP:0001873,DOID:1588	0-16
Myocardial ischaemia 0/19 (0.00%)	Adverse Events	5
Nausea 0/19 (0.00%)	Adverse Events	6
nausea	HP:0002018	0-6
Obstructive pancreatitis 1/19 (5.26%)	Adverse Events	7
pancreatitis	HP:0001733,DOID:4989	12-24
Vomiting 0/19 (0.00%)	Adverse Events	8
vomiting	HP:0002013	0-8
Fatigue 0/19 (0.00%)	Adverse Events	9
fatigue	HP:0012378	0-7
Generalised oedema 1/19 (5.26%)	Adverse Events	10
Pyrexia 1/19 (5.26%)	Adverse Events	11
Device related infection 1/19 (5.26%)	Adverse Events	12
Adverse Events 2:	Adverse Events	13
Total: 7/15 (46.67%)	Adverse Events	14
Anaemia 1/15 (6.67%)	Adverse Events	15
Atypical haemolytic uraemic syndrome 0/15 (0.00%)	Adverse Events	16
syndrome	DOID:225	28-36
Thrombocytopenia 3/15 (20.00%)	Adverse Events	17
thrombocytopenia	HP:0001873,DOID:1588	0-16
Myocardial ischaemia 1/15 (6.67%)	Adverse Events	18
Nausea 1/15 (6.67%)	Adverse Events	19
nausea	HP:0002018	0-6
Obstructive pancreatitis 0/15 (0.00%)	Adverse Events	20
pancreatitis	HP:0001733,DOID:4989	12-24
Vomiting 2/15 (13.33%)	Adverse Events	21
vomiting	HP:0002013	0-8
Fatigue 1/15 (6.67%)	Adverse Events	22
fatigue	HP:0012378	0-7
Generalised oedema 0/15 (0.00%)	Adverse Events	23
Pyrexia 0/15 (0.00%)	Adverse Events	24
Device related infection 0/15 (0.00%)	Adverse Events	25
